|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF292 |
Gene summary for ZNF292 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF292 | Gene ID | 23036 |
| Gene name | zinc finger protein 292 | |
| Gene Alias | MRD63 | |
| Cytomap | 6q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | O60281 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23036 | ZNF292 | CA_HPV_1 | Human | Cervix | CC | 4.42e-05 | -1.66e-01 | 0.0264 |
| 23036 | ZNF292 | CCI_1 | Human | Cervix | CC | 2.16e-10 | 1.48e+00 | 0.528 |
| 23036 | ZNF292 | CCI_2 | Human | Cervix | CC | 3.55e-08 | 9.84e-01 | 0.5249 |
| 23036 | ZNF292 | CCI_3 | Human | Cervix | CC | 8.69e-04 | 7.01e-01 | 0.516 |
| 23036 | ZNF292 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.31e-32 | -8.25e-01 | 0.0155 |
| 23036 | ZNF292 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.93e-07 | -5.31e-01 | -0.1808 |
| 23036 | ZNF292 | HTA11_2951_2000001011 | Human | Colorectum | AD | 4.41e-04 | -8.20e-01 | 0.0216 |
| 23036 | ZNF292 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.32e-12 | -7.83e-01 | -0.1207 |
| 23036 | ZNF292 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.39e-04 | -5.18e-01 | -0.1526 |
| 23036 | ZNF292 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.96e-16 | -4.82e-01 | -0.1464 |
| 23036 | ZNF292 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.29e-05 | -3.62e-01 | -0.1001 |
| 23036 | ZNF292 | HTA11_5212_2000001011 | Human | Colorectum | AD | 7.38e-03 | -6.89e-01 | -0.2061 |
| 23036 | ZNF292 | HTA11_5216_2000001011 | Human | Colorectum | SER | 6.88e-03 | -7.36e-01 | -0.1462 |
| 23036 | ZNF292 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.99e-03 | -6.20e-01 | -0.0179 |
| 23036 | ZNF292 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.73e-26 | -7.47e-01 | 0.096 |
| 23036 | ZNF292 | HTA11_8622_2000001021 | Human | Colorectum | SER | 5.98e-04 | -7.25e-01 | 0.0528 |
| 23036 | ZNF292 | HTA11_10623_2000001011 | Human | Colorectum | AD | 3.57e-07 | -7.72e-01 | -0.0177 |
| 23036 | ZNF292 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.45e-06 | -5.65e-01 | 0.0338 |
| 23036 | ZNF292 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.75e-17 | -6.03e-01 | 0.0674 |
| 23036 | ZNF292 | HTA11_11156_2000001011 | Human | Colorectum | AD | 1.05e-02 | -8.85e-01 | 0.0397 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF292 | SNV | Missense_Mutation | novel | c.176N>A | p.Leu59Gln | p.L59Q | O60281 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-EC-A1NJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.707N>T | p.Cys236Phe | p.C236F | O60281 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-EO-A1Y7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | portec3-radiation | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.7266N>G | p.Asn2422Lys | p.N2422K | O60281 | protein_coding | deleterious(0.04) | benign(0.214) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.1006N>A | p.Val336Ile | p.V336I | O60281 | protein_coding | deleterious(0.01) | probably_damaging(0.941) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.1333N>A | p.Glu445Lys | p.E445K | O60281 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.1963N>A | p.Asp655Asn | p.D655N | O60281 | protein_coding | deleterious(0.05) | possibly_damaging(0.889) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | novel | c.3217N>G | p.Phe1073Val | p.F1073V | O60281 | protein_coding | tolerated(0.23) | benign(0.182) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF292 | SNV | Missense_Mutation | rs377265584 | c.4927N>A | p.Ala1643Thr | p.A1643T | O60281 | protein_coding | tolerated_low_confidence(0.75) | benign(0.001) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| ZNF292 | SNV | Missense_Mutation | novel | c.4124N>G | p.Phe1375Cys | p.F1375C | O60281 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| ZNF292 | SNV | Missense_Mutation | novel | c.584N>T | p.Arg195Ile | p.R195I | O60281 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |